Skip to content

Clinical Study on Immunomodulatory Parenteral Nutrition Therapy for Severe Pneumonia Patients at Nutritional Risk

Clinical Study on Immunomodulatory Parenteral Nutrition Therapy for Severe Pneumonia Patients at Nutritional Risk

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2500106553
Enrollment
Unknown
Registered
2025-07-25
Start date
2025-08-01
Completion date
Unknown
Last updated
2025-08-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Severe Pneumonia

Interventions

observation group:None

Sponsors

TheThird People's Hospital of Chengdu
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 80 Years

Inclusion criteria

Inclusion criteria: 1. Definition of severe pneumonia. Meeting the diagnostic criteria for severe community-acquired pneumonia (SCAP) per the 2007 IDSA/ATS guidelines: fulfillment of 1 major criterion or =3 minor criteria.Major criteria include: (1) Respiratory failure requiring invasive mechanical ventilation; (2) Septic shock with persistent need for vasopressors despite adequate fluid resuscitation. Minor criteria include: (1) Respiratory rate >30 breaths/min; (2) Oxygenation index (PaO2/FiO2) 20 mg/dL; (6) Leukopenia (WBC =3, with indications for parenteral nutrition (when oral/enteral nutrition is unfeasible, insufficient, or contraindicated), hemodynamically stable, and eligible for nutritional support; 3.Aged 18–80 years (male or female); 4. Written informed consent must be obtained from the participant or their legal guardian prior to enrollment.

Exclusion criteria

Exclusion criteria: 1. Severe pneumonia patients with anticipated mortality within 48 hours of ICU admission; 2. Patients with contraindications to parenteral nutrition; 3. Presence of general intravenous fluid contraindications during screening period; 4. Known hypersensitivity to egg or soy protein, peanut protein, any active ingredient/excipient in the investigational product formulation, or fish oil-based lipid emulsion; history of drug allergies or allergic constitution; 5. Severe hyperlipidemia; recent myocardial infarction or stroke; severe hepatic or renal dysfunction; 6. Pregnant or lactating women; 7. Patients deemed by investigators to have any other factors unsuitable for trial participation.

Design outcomes

Primary

MeasureTime frame
Prealbumin before treatment;Albumin before treatment;Prealbumin after treatment;Albumin after treatment;

Secondary

MeasureTime frame
Lymphocyte count before treatment;Oxygenation index or oxygen saturation before treatment;Intravenous catheter-related fever;hospitalization time in ICU;Oxygenation index or oxygen saturation after treatment;Lymphocyte count after treatment;

Countries

China

Contacts

Public ContactWei Zeng

TheThird People's Hospital of Chengdu

456zw@163.com+86 159 0288 8821

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026